title: Unplugging JAK/STAT in Chronic Myelomonocytic Leukemia.
abstract: The proliferative component of chronic myelomonocytic leukemia, related to an increased sensitivity of myeloid progenitors to granulocyte macrophage-colony stimulating factor, suggests dedicated therapeutic approaches. In this issue, ruxolitinib, a JAK1 and -2 inhibitory drug, is shown to induce objective responses in chronic myelomonocytic leukemia patients. Clin Cancer Res; 22(15); 3707-9. ©2016 AACRSee related article by Padron et al., p. 3746.
authors.affiliation: Inserm U1170, Gustave Roussy, Villejuif, France. Faculty of Medicine, University Paris-Sud, Le Kremlin-Bicêtre, France. Eric.SOLARY@gustaveroussy.fr.
authors.forename: Eric
authors.initials: E
authors.lastname: Solary
mesh_terms: D000969:Antinematodal Agents / Q000627:therapeutic use*; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000378:metabolism*; D006801:Humans; D053612:Janus Kinases / Q000378:metabolism*; D015477:Leukemia, Myelomonocytic, Chronic / Q000188:drug therapy* / Q000378:metabolism*; D009570:Nitriles; D011720:Pyrazoles / Q000627:therapeutic use*; D011743:Pyrimidines; D050791:STAT Transcription Factors / Q000378:metabolism*; D015398:Signal Transduction / Q000187:drug effects; D016896:Treatment Outcome
chemical_list: D000969:Antinematodal Agents; D009570:Nitriles; D011720:Pyrazoles; D011743:Pyrimidines; D050791:STAT Transcription Factors; C540383:ruxolitinib; D016178:Granulocyte-Macrophage Colony-Stimulating Factor; D053612:Janus Kinases